Develops novel therapies for debilitating rare and orphan diseases. Focuses on conditions with high unmet medical needs in specialized patient populations. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 128% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Sales are growing strongly for its sector.
Clearly above the class average — a step short of the very top.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Business Quality: Profit power and business quality trail similar companies in the sector.
The stock trades 24% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 128% a year on average.
The company sells $521.3M a year; the problem isn’t sales — it’s costs running above that number.
There is $383.3M in the vault; even if every debt were paid off, $63.9M would remain.
A loss of $23.4M against $521.3M in annual sales.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 43/100.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 44/100.
On our five-subject report card, MIRM sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: MIRM has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (47/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.